Cincinnati, OH, May 9, 2022 — Sus Clinicals, Inc.TM announced today that Jeffrey C. Sinclair will be serving as an advisor to Company leadership, helping shape the Company’s approach to leveraging the Oncopig Cancer ModelTM (OCM) to support the work of cancer researchers around the world.
Sus Clinicals accelerates qualification of life-saving cancer therapeutics through proprietary pig-based pre-clinical testing services. In collaboration with top research institutions, the Company’s FDA-cleared, predictive large animal model can more quickly identify drugs, diagnostics and devices that have the highest potential for success in human clinical trials, allowing its clients to focus their resources and advance more quickly to in-market success.
“I’m delighted that Jeff has agreed to come on board as an advisor,” said Jeffrey D. Weedman, Co-founder and Chief Executive Officer. “I’ve known Jeff Sinclair for more than a decade, and I’ve always been impressed with his ability not only to get to the heart of an issue, but to articulate actionable approaches to identifying solutions.”
Jeff Sinclair retired from McKinsey & Company after a 32 year career. Serving as Director and Senior Partner, Jeff worked with clients in North America, Asia, and Europe on strategy, operations, and organization in High Tech & Electronics, Aerospace & Defense, Automotive, Industrial, Consumer Products, and Government. He held multiple leadership roles in the Operations Practice, including: Service Line Leader for Manufacturing, Supply Chain, and Product Development; and Global Knowledge Leader across Product Development, Purchasing, Manufacturing, Supply Chain, and Service Operations.
Following his retirement from McKinsey, Jeff returned to his alma mater, the University of Michigan, where he serves as Adjunct Professor. He brings extensive “real world” experience to his teaching across general management, entrepreneurship, and consulting in the Ross School of Business.
“I find Sus Clinicals’ mission of helping cancer researchers save lives very compelling,” said Sinclair. “Jeff Weedman has assembled a terrific team to bring that mission to life. I look forward to helping support them as they make key decisions around organization design, scaling strategies and operational effectiveness.”
Sus Clinicals is headquartered in Cincinnati, Ohio, with scientific facilities in Chicago and Urbana, Illinois.
